Evandro de Azambuja, President of the Belgian Society of Medical Oncology (BSMO) for 2023-2026, shared a post on LinkedIn about a paper he co-authored with his colleagues, published in NEJM:
“Truly honored to participate in this practice-changing trial.
Improving patient outcomes is the most rewarding aspect of our career.
In a phase 3 trial of previously untreated, PD-L1–positive advanced triple-negative Breast Cancer, sacituzumab govitecan plus pembrolizumab significantly improved progression-free survival compared with chemotherapy plus pembrolizumab.
The combination also achieved higher and more durable response rates. Safety was comparable between groups, with fewer treatment discontinuations in the sacituzumab govitecan arm. Overall survival data were not yet mature.”
Title: Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
Authors: Sara M Tolaney, Evandro de Azambuja, Kevin Kalinsky, Sherene Loi, Sung Bae Kim, Clinton Yam, Bernardo Rapoport, Seock Ah Im, Barbara Pistilli, Wassim Mchayleh, David W Cescon, Junichiro Watanabe, Manuel Alejandro Lara Banuelas, Ruffo Freitas Junior, Javier Salvador Bofill, Maryam Afshari, Dianna Gary, Lu Wang, Catherine Lai, Peter Schmid
More posts featuring Evandro de Azambuja.